SCHEMBL24673520

SCHEMBL24673520

CCCN(C)CCCCCCCCCC(C)C

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.44
CHRM2 P08172 1/20 0.41
GGPS1 O95749 3/20 0.40
LMNA P02545 2/20 0.39
S1PR2 O95136 1/20 0.38
S1PR1 P21453 1/20 0.38
S1PR3 Q99500 1/20 0.38
S1PR5 Q9H228 1/20 0.38
DNM1 Q05193 3/20 0.37
KDM4C Q9H3R0 3/20 0.37
KDM5A P29375 1/20 0.37
PLA2G1B P04054 1/20 0.36
PLA2G2A P14555 1/20 0.36
KDM4A O75164 1/20 0.34
PHF8 Q9UPP1 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15535769 1.00 SIGMAR1 (0.44) SIGMAR1CHRM2GGPS1LMNAS1PR2
SCHEMBL22837700 1.00 SIGMAR1 (0.44) SIGMAR1CHRM2GGPS1LMNAS1PR2
SCHEMBL10225216 1.00 SIGMAR1 (0.44) SIGMAR1CHRM2GGPS1LMNAS1PR2
SCHEMBL20028367 0.98 SIGMAR1 (0.41) SIGMAR1CHRM2GGPS1LMNAS1PR2
SCHEMBL25562392 0.91 GGPS1 (0.44) CHRM2GGPS1LMNAS1PR2S1PR1
SCHEMBL8958250 0.91 GGPS1 (0.48) CHRM2GGPS1LMNAS1PR2S1PR1
SCHEMBL19364106 0.91 GGPS1 (0.48) CHRM2GGPS1LMNAS1PR2S1PR1
SCHEMBL28092012 0.91 GGPS1 (0.44) CHRM2GGPS1LMNAS1PR2S1PR1
SCHEMBL8958562 0.91 GGPS1 (0.48) CHRM2GGPS1LMNAS1PR2S1PR1
SCHEMBL28094543 0.91 GGPS1 (0.48) CHRM2GGPS1LMNAS1PR2S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4393922-A1 IRAK4 DEGRADATION AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-07-03 EP disclosed
EP-4328219-A1 SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) 2024-02-28 EP disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-09 US disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 SIGMAR1 2878/4885CHRM2 3335/4885GGPS1 567/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 SIGMAR1 1749/4885CHRM2 4663/4885GGPS1 2355/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 SIGMAR1 3199/4885CHRM2 4681/4885GGPS1 2757/4885
US-20230072658-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 SIGMAR1 2336/4885CHRM2 1891/4885GGPS1 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.